Pancreatic Cancer Success: Dolores House's Targeted Treatment Recognized by ASCO
Dolores House, a western New York woman, has become a success story in the fight against pancreatic cancer. Her treatment, guided by 'gastrointestinal molecular profiling', has shown remarkable results. This innovative approach has been recognised by the American Society of Clinical Oncology (ASCO) as the 'Advance of the Year' for 2021.
House was diagnosed with a rare genetic subtype of pancreatic cancer at the Wilmot Cancer Institute. Instead of standard chemotherapy, she benefited from the immunotherapy drug Keytruda. This targeted treatment was made possible by the institute's application of 'gastrointestinal molecular profiling'. The analysis revealed a specific biomarker in House's tumor, allowing doctors to tailor her treatment.
About 20% of gastrointestinal (GI) cancer patients at Wilmot Cancer Institute have seen treatment benefits from this profiling. The institute serves a 27-county region in upstate New York and is at the forefront of using molecular test results to guide treatment plans. It is particularly focused on finding new ways to treat pancreatic cancer using both immune and non-immune therapies. In younger patients, the analysis can also uncover genetic factors that may warrant genetic counseling.
Dolores House's tumor markers have significantly decreased, almost to nothing, following her Keytruda infusions at the Wilmot Cancer Institute. This success underscores the potential of 'gastrointestinal molecular profiling' in improving cancer treatment outcomes. The ASCO's recognition of this approach as the 'Advance of the Year' 2021 highlights its promise in the broader fight against cancer.
Read also:
- Intestinal Infection Causing Stomach Distress: Signs and Remedies
- What is the expected timing for the flu season in this current year?
- Essential Information on Cushing Syndrome: a Disorder Caused by High Cortisol Levels
- Starting in September, elderly individuals aged 75 years and above will be enrolled in a preventive program for Respiratory Syncytial Virus (RSV).
